美国肝素诱导的血小板减少症疾病负担、并发症发生率及医疗费用:一项基于人群的研究
该研究分析2009至2013年美国全国住院患者样本中肝素诱导的血小板减少症(HIT)出院记录,估计其疾病负担、并发症率与费用。HIT发生率为0.065%(约每1500例住院中1例),血栓形成占29.8%、出血占6.2%,截肢和院内死亡风险显著高于非HIT出院。
要点
- HIT总体发生率为0.065%(SE 0.0012),约每1500例住院中1例。
- 体外循环患者HIT发生率最高(0.63%),髋/膝关节置换术最低。
- HIT患者截肢调整OR 5.095,院内死亡调整OR 4.075,均显著高于非HIT。
核心结论
- HIT并发症发生率仍高,需要更有效的预防和治疗干预。
研究设计与样本
- 基于人群研究,分析2009至2013年美国全国住院患者样本(NIS)数据,共纳入97 566例HIT出院和149 911 247例非HIT出院。
- 使用2013年当地医院(Froedtert Memorial Lutheran Hospital,密尔沃基,威斯康星州,美国)患者数据验证ICD-9-CM编码289.84的灵敏度和特异度。
主要发现
- 2009至2013年间,HIT在97 566/150 008 813例出院中被识别(0.065%;SE 0.0012),约每1500例住院中1例。
- 体外循环患者HIT发生率最高(7702/1 230 362,0.63%;SE 0.03),其次为血液透析(23 012/4 908 100,0.47%;SE 0.01)、牙龈或牙周疾病(106/88 621,0.12%;SE 0.03)、创伤或损伤(541/602 944,0.09%;SE 0.01);髋关节置换(845/1 943 353,0.04%;SE 0.004)和膝关节置换(676/3 022 602,0.02%;SE 0.002)最低。
- 血栓形成29 079/97 566(29.8%;SE 0.4),出血6044/97 566(6.2%;SE 0.2);HIT合并出血患者中1446/6044死亡(23.9%;SE 1.2)。
- HIT出院截肢742/97 566(0.76%;SE 0.06) vs 非HIT出院173 043/149 911 247(0.12%;SE 0.001),调整OR 5.095(95%CI 4.309-6.023;p<0.0001)。
- HIT出院院内死亡9842/97 508(10.1%;SE 0.2) vs 非HIT出院3 206 700/149 811 891(2.1%;SE 0.01),调整OR 4.075(95%CI 3.846-4.317;p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin-induced thrombocytopenia can be a life-threatening and limb-threatening complication of heparin therapy. Incidence and complication rates of this condition have been extrapolated from studies with modest sample sizes, and despite the availability of therapeutic interventions the outcomes of heparin-induced thrombocytopenia are not well understood. We aimed to estimate disease burden, complication rates, and costs of heparin-induced thrombocytopenia in the USA. METHODS: In this population-based study we analysed data from 2009 to 2013 from the Nationwide (National) Inpatient Sample (NIS), a large, all-payer inpatient health-care database in the USA. To validate the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for heparin-induced thrombocytopenia (289.84), we defined the sensitivity and specificity of this code using patient data from 2013 from a local hospital (Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA). The primary outcomes assessed were the incidence of hospital discharges with codes for heparin-induced thrombocytopenia and of discharges for heparin-induced thrombocytopenia associated with cardiopulmonary bypass, haemodialysis, hip or knee arthroplasty, trauma or injury (or both), and gingival or periodontal disease (or both). We also assessed the incidence of thrombosis, bleeding, limb or digit amputation, mortality, length of hospital stay, and associated hospital charges. FINDINGS: Between 2009 and 2013, 97 566 discharges from the NIS assigned the ICD-9-CM code for heparin-induced thrombocytopenia, and 149 911 247 discharges coded for non-heparin-induced thrombocytopenia, were analysed. Overall, heparin-induced thrombocytopenia was identified in 97 566 (0·065%; SE 0·0012) of 150 008 813 discharges, corresponding to approximately one in 1500 hospital admissions. Patients undergoing cardiopulmonary bypass had the highest rates of heparin-induced thrombocytopenia (7702 [0·63%; SE 0·03] of 1 230 362), followed by those undergoing haemodialysis (23 012 [0·47%; 0·01] of 4 908 100), those with gingival or periodontal disease, or both (106 [0·12%; 0·03] of 88 621), and those with trauma or injury, or both (541 [0·09%; 0·01] of 602 944); patients with hip (845 [0·04%; 0·004] of 1 943 353) and knee (676 [0·02%; 0·002] of 3 022 602) arthroplasty had the lowest rates of heparin-induced thrombocytopenia. Thrombosis (29 079 [29·8%; SE 0·4] of 97 566) and bleeding (6044 [6·2%; 0·2] of 97 566) were common complications in heparin-induced thrombocytopenia, and 1446 (23·9%; 1·2) of 6044 patients with heparin-induced thrombocytopenia who had haemorrhage died. 742 (0·76%; SE 0·06) of 97 566 patients with heparin-induced thrombocytopenia discharges underwent amputations compared with 173 043 (0·12%; 0·001) of 149 911 247 with non-heparin-induced thrombocytopenia discharges (adjusted odds ratio 5·095 [95% CI 4·309-6·023]; p<0·0001). Overall, in-hospital mortality was 9842 (10·1%; SE 0·2) of 97 508 in discharge summaries coded for heparin-induced thrombocytopenia compared with 3 206 700 (2·1%; 0·01) of 149 811 891 in discharges for non-heparin-induced thrombocytopenia (adjusted odds ratio 4·075 [95% CI 3·846-4·317]; p<0·0001). The median length of stay among live discharges was 8·9 days (IQR 4·6-17·1) and total hospital charges were US$83 072 (IQR 37 240-188 419) for heparin-induced thrombocytopenia discharges compared with 2·6 days (1·4-4·8) and $21 360 (11 426-41 917) for non-heparin-induced thrombocytopenia discharges (p<0·0001 for both). 333 discharges from a local hospital were analysed to assess the diagnostic sensitivity and specificity of the heparin-induced thrombocytopenia ICD-9-CM code; sensitivity was 90·9% (95% CI 57·1-99·5) and specificity was 94·4% (91·1-96·6). INTERPRETATION: Complication rates for heparin-induced thrombocytopenia remain high and more effective preventive and treatment interventions are needed. FUNDING: None.
引用
- Dhakal B, Kreuziger LB, Rein L, et al. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol. 2018. PMID: 29703336. doi:10.1016/S2352-3026(18)30046-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。